

Notice of Allowability	Application No.	Applicant(s)	
	10/009,122	CHALIFOUR ET AL.	
	Examiner	Art Unit	
	Samuel W. Liu	1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 12/5/05.
2. ☒ The allowed claim(s) is/are 1,8,20,21,32 and 39-54.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☒ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☒ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|--|
| 1. <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date <u>1/4/06</u> . |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____. |

Art Unit: 1653

DETAILED ACTION

This Office action is in response to the applicants' amendment filed 12/5/05, which amends claims 1, 8, 20 and 41, adds claims 43-48, and cancels claims 2-7, 9-19, 22-31, 33-38. The stated amendment has been entered. The pending claims 1, 8, 20-21, 32 and 39-54 are examined in this Office action.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Susan M. Michaud on January 4, 2006. Applicants agree the Examiner proposed amendment to claims 1 and 8 (see below).

Amendments to the claim:

The pending claims 1 and 8 have been amended as follows. Please replace the previous claims with the claims shown below.

Claim 1 (*Amended*): Before "consisting of all [D]-amino acids" (lines 2 and 3) delete "of Formula I", and before "is selected from the group...", delete "of Formula I".

Claim 8 (*Amended*): An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide consisting of all [D]-amino acids, or a retro-isomer of a peptide consisting of all [D]-amino acids, wherein said peptide is ~~a peptide of SEQ ID NO:2~~.

Amendments to the specification:

Art Unit: 1653

On page 11, line 12, change “*Fig. 2 illustrates a thioflavin T fluorescence assay ...*” to “Fig. 2 illustrates the result of a thioflavin T fluorescence assay ...”.

On page 11, line 16, change “*Fig. 3 shows the same assay ...*” to “Fig. 3 shows the result of the same assay...”.

Objection to the drawings:

The drawings filed 11/05/01 are objected to because (i) the labels of “Figure 1, 2, 3, 4, 5, 6, and 7” *per se* is vaguely presented; (ii) in Figures 2 and 3, the unit of “incubation time”, i.e., “(d)” is unclear; the corresponding clarification in this regard is required; and (iii) in Figure 5, at the upper left corner, “48 h” does not appear to belong to the figure.

The following is an **Examiner's Statement of Reasons for Allowance**: The prior art does not fairly teach or suggest the disclosed antifibrillogenic agent comprising the peptide of SEQ ID NO:1, 2, 4, 7, 9, 10, 12, 15, 17, 18 or 19 wherein the peptide consisting of all D-form amino acids, or is a retro-isomer thereof. In view of “cytoprotection”, the cytoprotective function of beta amyloid related polypeptide/peptide or derivative thereof is known in the art (see Wehner et al. (2004) *Eur. J. Cell Biol.* 83, 701-708). In light of the applicants' amendment filed 12/05/05, the rejections under 35 USC 102 and 103 set forth in the Office action mailed 10/04/05 are thus withdrawn.

Conclusion: claims 1, 8, 20-21, 32 and 39-54 are allowed.

Any comments considered necessary by applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Jon Weber, can be reached at (571) 272-0925. The official fax number for Technology Center 1600 is (703) 308-4242. Any inquiry of a general nature or relating to the

Art Unit: 1653


status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.



Samuel W. Liu, Ph.D.

Art Unit 1653, Examiner

January 4, 2006



JON WEBER
SUPERVISORY PATENT EXAMINER